Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 6.42
PIP's Cash to Debt is ranked higher than
70% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 68.42 vs. PIP: 6.42 )
PIP' s 10-Year Cash to Debt Range
Min: 0.03   Max: No Debt
Current: 6.42

Equity to Asset 0.58
PIP's Equity to Asset is ranked higher than
75% of the 751 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. PIP: 0.58 )
PIP' s 10-Year Equity to Asset Range
Min: -0.53   Max: 0.8
Current: 0.58

-0.53
0.8
F-Score: 3
Z-Score: -10.04
M-Score: -4.08
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -60.51
PIP's Operating margin (%) is ranked higher than
72% of the 794 Companies
in the Global Biotechnology industry.

( Industry Median: -68.50 vs. PIP: -60.51 )
PIP' s 10-Year Operating margin (%) Range
Min: -873.96   Max: 55.46
Current: -60.51

-873.96
55.46
Net-margin (%) -65.42
PIP's Net-margin (%) is ranked higher than
72% of the 794 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. PIP: -65.42 )
PIP' s 10-Year Net-margin (%) Range
Min: -909.98   Max: 47.27
Current: -65.42

-909.98
47.27
ROE (%) -159.73
PIP's ROE (%) is ranked higher than
52% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. PIP: -159.73 )
PIP' s 10-Year ROE (%) Range
Min: -1024.11   Max: 0.49
Current: -159.73

-1024.11
0.49
ROA (%) -68.37
PIP's ROA (%) is ranked higher than
56% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -17.51 vs. PIP: -68.37 )
PIP' s 10-Year ROA (%) Range
Min: -128.13   Max: 0.4
Current: -68.37

-128.13
0.4
ROC (Joel Greenblatt) (%) -2808.03
PIP's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 876 Companies
in the Global Biotechnology industry.

( Industry Median: -201.33 vs. PIP: -2808.03 )
PIP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2808.03   Max: 0.48
Current: -2808.03

-2808.03
0.48
Revenue Growth (%) -18.60
PIP's Revenue Growth (%) is ranked higher than
65% of the 638 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. PIP: -18.60 )
PIP' s 10-Year Revenue Growth (%) Range
Min: -30.1   Max: 173.4
Current: -18.6

-30.1
173.4
EBITDA Growth (%) -36.50
PIP's EBITDA Growth (%) is ranked higher than
57% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. PIP: -36.50 )
PIP' s 10-Year EBITDA Growth (%) Range
Min: -66.7   Max: -20
Current: -36.5

-66.7
-20
EPS Growth (%) -40.30
PIP's EPS Growth (%) is ranked higher than
58% of the 636 Companies
in the Global Biotechnology industry.

( Industry Median: -12.20 vs. PIP: -40.30 )
PIP' s 10-Year EPS Growth (%) Range
Min: -64.7   Max: -9.1
Current: -40.3

-64.7
-9.1
» PIP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

PIP Guru Trades in Q3 2013

Jim Simons 146,300 sh (New)
» More
Q4 2013

PIP Guru Trades in Q4 2013

Jim Simons 40,500 sh (-72.32%)
» More
Q1 2014

PIP Guru Trades in Q1 2014

Jim Simons 21,700 sh (-46.42%)
» More
Q2 2014

PIP Guru Trades in Q2 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with PIP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 13.06
PIP's P/B is ranked lower than
53% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. PIP: 13.06 )
PIP' s 10-Year P/B Range
Min: 1.3   Max: 31.64
Current: 13.06

1.3
31.64
P/S 6.97
PIP's P/S is ranked higher than
68% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 17.18 vs. PIP: 6.97 )
PIP' s 10-Year P/S Range
Min: 0.44   Max: 103.75
Current: 6.97

0.44
103.75
EV-to-EBIT -8.70
PIP's EV-to-EBIT is ranked higher than
61% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PIP: -8.70 )
PIP' s 10-Year EV-to-EBIT Range
Min: 109.1   Max: 199.6
Current: -8.7

109.1
199.6
Current Ratio 3.34
PIP's Current Ratio is ranked higher than
74% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 3.97 vs. PIP: 3.34 )
PIP' s 10-Year Current Ratio Range
Min: 0.41   Max: 389.51
Current: 3.34

0.41
389.51
Quick Ratio 3.34
PIP's Quick Ratio is ranked higher than
75% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. PIP: 3.34 )
PIP' s 10-Year Quick Ratio Range
Min: 0.41   Max: 389.51
Current: 3.34

0.41
389.51

Valuation & Return

vs
industry
vs
history
Price/Net Cash 29.85
PIP's Price/Net Cash is ranked higher than
67% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PIP: 29.85 )
PIP' s 10-Year Price/Net Cash Range
Min: 3.26   Max: 186
Current: 29.85

3.26
186
Price/Net Current Asset Value 23.22
PIP's Price/Net Current Asset Value is ranked higher than
65% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 169.30 vs. PIP: 23.22 )
PIP' s 10-Year Price/Net Current Asset Value Range
Min: 2.84   Max: 47
Current: 23.22

2.84
47
Price/Tangible Book 19.00
PIP's Price/Tangible Book is ranked lower than
54% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 8.60 vs. PIP: 19.00 )
PIP' s 10-Year Price/Tangible Book Range
Min: 1.48   Max: 37
Current: 19

1.48
37
Price/Median PS Value 2.35
PIP's Price/Median PS Value is ranked lower than
52% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. PIP: 2.35 )
PIP' s 10-Year Price/Median PS Value Range
Min: 0.23   Max: 34.17
Current: 2.35

0.23
34.17
Forward Rate of Return (Yacktman) -70.61
PIP's Forward Rate of Return (Yacktman) is ranked higher than
59% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. PIP: -70.61 )
PIP' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 16.7   Max: 19.5
Current: -70.61

16.7
19.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NONOF, AMGN, GILD, BIIB, CELG » details
PharmAthene, Inc., was incorporated under the laws of the State of Delaware as Healthcare Acquisition Corp. (HAQ) on April 25, 2005. On August 3, 2007, HAQ consummated a merger with PharmAthene, Inc. and changed its name from Healthcare Acquisition Corp. to PharmAthene, Inc. It is a biodefense company, which is engaged in the development and commercialization of medical countermeasures against biological and chemical weapons. Its biodefense portfolio includes the product candidates namely SparVax, a second generation recombinant protective antigen (rPA) anthrax vaccine; Valortim, a fully human monoclonal antibody for the prevention and treatment of anthrax infection, and; rBChE (recombinant butyrylcholinesterase) bioscavanger, a medical countermeasure for nerve agent poisoning by organophosphorous compounds, including nerve gases and pesticides. The Company's customers are the U.S. Department of Defense (the DoD), the National Institute of Allergy and Infectious Diseases ('NIAID), the Biomedical Advanced Research and Development Authority ('BARDA'), and the National Institute of Health (NIH). The Company is subject to various federal, state and local laws, regulations and recommendations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with its various activities.
» More Articles for PIP

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: BWEN, ENZ, PIP, HAFC, AACC Nov 21 2011 
PharmAthene Inc (PIP) CEO Eric I Richman buys 10,000 Shares Jun 21 2010 
Guru Activities for Today’s Price % Losers: PharmAthene Inc. , Authentidate Holding Corp., Kroger Dec 08 2009 

More From Other Websites
PHARMATHENE, INC Financials Aug 15 2014
Jazz Pharmaceuticals (JAZZ) in Focus: Stock Surges 8.8% Aug 14 2014
PharmAthene May Get $500 Million From Smallpox Drug Sales Aug 12 2014
Why SIGA Technologies (SIGA) Stock Plunged to a One-Year Low Today Aug 11 2014
Why PharmAthene (PIP) Stock Is Soaring Today Aug 11 2014
Why PharmAthene Is Up 56% In #PreMarket Trading Aug 11 2014
[$$] Court Rules in PharmAthene's Favor Aug 11 2014
PHARMATHENE, INC Files SEC form 8-K, Other Events Aug 11 2014
Delaware Court of Chancery Orders SIGA To Pay PharmAthene Lump Sum Expectation Damages Aug 10 2014
Q2 2014 PharmAthene, Inc. Earnings Release- Tentative - Time Not Supplied Aug 07 2014
PHARMATHENE, INC Files SEC form 10-Q, Quarterly Report Aug 05 2014
PharmAthene Reports Second Quarter 2014 Financial And Operational Results Aug 04 2014
PHARMATHENE, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 04 2014
PharmAthene Reports Second Quarter 2014 Financial And Operational Results Aug 04 2014
PharmAthene Vs. SIGA: Rebutting G. Hudson's 'Potential Award' Article Jul 24 2014
Explanation Of Potential Damage Award In PharmAthene Versus Siga Lawsuit Jul 22 2014
PHARMATHENE, INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 12 2014
PharmAthene announces U.S. patent for recombinant bioscavenger Jun 09 2014
PharmAthene Granted U.S. Patent For Recombinant Bioscavenger Jun 09 2014
PharmAthene Presents New SparVax® Anthrax Vaccine Data At The FDA Medical Countermeasures... Jun 04 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide